Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
- Monday, October 26, 2020, 7:00
- Finance
- Add a comment
TARRYTOWN, N.Y. and PARIS, Oct. 26, 2020 /PRNewswire/ — First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older New late-breaking…
About the Author
adminasapcorp has written 39734 stories on this site.